Neurology
Merck Serono commits considerable research effort to finding increasingly effective treatments for Multiple Sclerosis (MS)
and, through biotechnology, brings greater hope to people affected by this debilitating condition.
Our treatment for MS, Rebif®, is approved in over 80 countries worldwide. The use of the latest recombinant biological technology
allows Merck Serono to synthesise Rebif, which is identical to the interferon beta-1a protein produced naturally by the human
body.
Multiple Sclerosis at a glance-
MS is a disease of the central nervous system and can affect the brain, the spinal cord and the optic nerves. It is usually diagnosed between the ages of 20 and 40 and is twice as common in women than in men
-
MS interferes with the brain's ability to control such normal functions as walking, talking and the ability to see. It is unpredictable and every person with MS will have a unique set of symptoms
-
The disease and its progression are highly unpredictable and can lead to varying levels of disability
